Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Life science behemoths - R.I.P.

OXFORD - It has taken only a year and a half to bury the fantasy of the fully integrated life sciences company model, which postulated ephemeral synergies between drug, agbio, agrichemical and nutriceuticals businesses. Last week's decision by Novartis AG and AstraZeneca plc to spin out and merge their agribusinesses to form Syngenta AG, leaving two stand-alone pharmaceutical companies, will now focus attention on how the

Read the full 665 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers